Viking Therapeutics (VKTX) recently launched a Phase 1 single ascending dose study of VK3019, a Dual Amylin and Calcitonin Receptor Agonist being tested as a potential weight loss therapy in adults with obesity.

The VK3019 update comes as Viking Therapeutics shares trade at $36.37, with the stock down 11.59% over the past week but up 22.66% on a 30 day share price return and supported by a very large 5 year total shareholder return of more than 7x, which points to solid long term momentum despite recent volatility.

If this kind of obesity and metabolic drug story has your attention, it can be useful to compare it with other health focused AI opportunities using the 39 healthcare AI stocks.

After Viking Therapeutics slipped over the past week yet still shows a strong multi year share price gain, the practical question is whether to accept today’s entry point or instead wait for a pullback that better fits the valuation.

Most Popular Narrative: 60.8% Undervalued

With Viking Therapeutics closing at $36.37 against a narrative fair value of $92.72, the current price sits well below that implied level and puts the focus firmly on what assumptions are doing the heavy lifting.

Parallel development of subcutaneous and oral formulations of the same GLP 1 and GIP co agonist, including plans to start Phase III oral trials and an oral maintenance strategy, directly responds to rising patient interest in flexible obesity treatment options and could support broader market reach and future earnings growth.

Want to see why this obesity pipeline supports such a big gap to $92.72? The narrative leans heavily on future revenue, margin uplift and a rich earnings multiple. Curious which assumptions matter most and how sensitive that fair value is to small changes?

Result: Fair Value of $92.72 (UNDERVALUED)

However, Viking Therapeutics still carries clear execution risk, with no current revenue, sizeable 2025 net losses, and heavy R&D spending that could mean future dilution if trials disappoint.

Another View: Viking Therapeutics Looks Expensive on Book Value

While the analyst narrative flags Viking Therapeutics as undervalued versus a $92.72 fair value, the current P/B ratio of 8.4x sits well above both the US Biotechs industry at 2.6x and the peer average of 6x. This points to richer expectations baked into the share price. If the market gravitates closer to an eventual fair ratio, could that premium narrow faster than the obesity story plays out?

Next Steps

With mixed signals on valuation and sentiment around Viking Therapeutics, it makes sense to check the numbers yourself and form an independent view using the 2 important warning signs.

Looking for more investment ideas beyond Viking Therapeutics?

If Viking Therapeutics has sharpened your focus on high conviction opportunities, do not stop here. Use these tools to pressure test and broaden your watchlist immediately:

• Target steady potential by reviewing companies that score well on financial resilience and fundamentals using the solid balance sheet and fundamentals stocks screener (47 results).
• Hunt for quality at attractive prices by scanning companies currently flagged as having room between fundamentals and market expectations through the 49 high quality undervalued stocks.
• Spot early stage opportunities that still pass basic financial filters by checking the 20 elite penny stocks with strong financials before they come onto everyone else's radar.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.